Janux Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
JANX Nasdaq 2834 www.januxrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Janux Therapeutics, Inc.

Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Dec 27th, 2025 5:43 am
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - Dec 23rd, 2025 2:05 pm
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Dec 12th, 2025 5:30 am
Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test? - Dec 6th, 2025 4:09 am
Janux Therapeutics (JANX): Valuation Check After Positive JANX007 Phase 1 Data and Sharp Share Price Drop - Dec 4th, 2025 8:16 pm
Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'? - Dec 2nd, 2025 2:14 pm
Sector Update: Health Care Stocks Softer Late Afternoon - Dec 2nd, 2025 1:53 pm
Top Midday Decliners - Dec 2nd, 2025 12:25 pm
Janux dives as gaps in prostate cancer study data worry investors - Dec 2nd, 2025 8:50 am
Janux Therapeutics Stock Craters After ‘Positive’ Cancer Data. Why It’s Down 50%. - Dec 2nd, 2025 7:53 am
Traders Tread Cautiously as Key Inflation Metric Looms, Driving Narrow Premarket Gains for US Equity Futures - Dec 2nd, 2025 7:13 am
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Investors Seek Catalysts - Dec 2nd, 2025 6:42 am
Janux sinks on ‘overreaction’ to prostate cancer data; RFK Jr. replaces ACIP chair - Dec 2nd, 2025 3:15 am
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC - Dec 1st, 2025 2:05 pm
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC - Nov 24th, 2025 6:00 am
Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program - Nov 16th, 2025 8:13 pm
Why Janux Therapeutics (JANX) Draws Analyst Optimism Despite Widening Year-to-Date Losses - Nov 9th, 2025 12:06 am
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2025 4:10 pm
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - Nov 6th, 2025 2:01 pm
Wave Life Sciences (WVE) Soars 8.8%: Is Further Upside Left in the Stock? - Oct 30th, 2025 3:53 am